A human protein required for the second step of pre-mRNA splicing is functionally related to a yeast splicing factor.

D S Horowitz and A R Krainer

*Genes Dev.* 1997 11: 139-151
Access the most recent version at doi:10.1101/gad.11.1.139

---

**References**

This article cites 74 articles, 46 of which can be accessed free at:
http://genesdev.cshlp.org/content/11/1/139.full.html#ref-list-1

**Email Alerting Service**

Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or click here.

---

To subscribe to *Genes & Development* go to:
http://genesdev.cshlp.org/subscriptions

Copyright © Cold Spring Harbor Laboratory Press
A human protein required for the second step of pre-mRNA splicing is functionally related to a yeast splicing factor

David S. Horowitz and Adrian R. Krainer

Cold Spring Harbor Laboratory, Cold Spring Harbor, New York 11724 USA

We have identified a human splicing factor required for the second step of pre-mRNA splicing. This new protein, hPrp18, is 30% identical to the yeast splicing factor Prp18. In HeLa cell extracts immunodepleted of hPrp18, the second step of pre-mRNA splicing is abolished. Splicing activity is restored by the addition of recombinant hPrp18, demonstrating that hPrp18 is required for the second step. The hPrp18 protein is bound tightly to the spliceosome only during the second step of splicing. hPrp18 is required for the splicing of several pre-mRNAs, making it the first general second-step splicing factor found in humans. Splicing activity can be restored to hPrp18-depleted HeLa cell extracts by yeast Prp18, showing that important functional regions of the proteins have been conserved. A 90-amino-acid region near the carboxyl terminus of hPrp18 is strongly homologous to yeast Prp18 and is also conserved in rice and nematodes. The homology identifies one region important for the function of both proteins and may define a new protein motif. In contrast to yeast Prp18, hPrp18 is not stably associated with any of the snRNPs. A 55-kD protein that cross-reacts with antibodies against hPrp18 is a constituent of the U4/U6 and U4/U6·U5 snRNP particles.

[Key Words: Pre-mRNA splicing; splicing factor; Prp18; U4/U6 snRNP]

Received September 2, 1996; revised version accepted November 25, 1996.

The splicing of pre-mRNA takes place in two sequential transesterification reactions [for review, see Umen and Guthrie 1995c; Adams et al. 1996; Krämer 1996]. In the first step, the 2' hydroxyl group of an adenosine within the intron attacks the phosphate at the 5' splice site, forming the lariat intron–exon2 and exon1 intermediates. mRNA and lariat intron are produced in the second step by attack of the 3' hydroxyl group of exon1 on the phosphate at the 3' splice site. The second reaction occurs within an assembled spliceosome that contains the U2, U5, and U6 small nuclear ribonucleoproteins (snRNPs) and a large number of proteins.

Several proteins required specifically for the second step—Prp16, Prp17, Prp18, and Slu7—have been studied in yeast, but in humans much less is known about the proteins involved in the second step [Umen and Guthrie 1995c]. PRPT8 was discovered in a screen for yeast mutants that were temperature-sensitive for pre-mRNA splicing [Vijayraghavan et al. 1989]. The Prp18 protein is involved only in the second step of pre-mRNA splicing and is associated with the U5 snRNP [Vijayraghavan and Abelson 1990; Horowitz and Abelson 1993a,b]. Prp18 is not essential for yeast viability, although the second step of splicing is extremely slow without it. The sequence of Prp18 is not instructive, and the precise function of Prp18 in the splicing reaction is not known. The Prp16 protein, initially found as a suppressor of a branch site mutation [Couto et al. 1987], is an RNA-dependent ATPase that catalyzes a conformational change in the spliceosome before the second splicing reaction [Schwer and Guthrie 1991, 1992]. Prp17 is not an essential protein, and its function in splicing remains unknown [Jones et al. 1995]. Slu7, which was isolated based on its genetic interaction with the U5 snRNA [Frank et al. 1992], is involved in the recognition of 3' splice sites [Frank and Guthrie 1992]. Finally, the Prp8 protein, initially shown to be a first-step splicing factor [Lustig et al. 1986], is also required for the second step and appears to be involved in 3' splice-site recognition [Teigelkamp et al. 1995; Umen and Guthrie 1995a,b].

Genetic studies suggest that there is a network of interactions among these second-step proteins [Frank et al. 1992; Jones et al. 1995; Umen and Guthrie 1995b]. Biochemical experiments have distinguished two stages within the second step. The first stage requires the Prp16 and Prp17 proteins, as well as the hydrolysis of ATP; the second stage, during which the transesterification reaction occurs, requires Prp18 and Slu7 and is independent of ATP [Schwer and Guthrie 1991; Horowitz and Abelson 1993a; Ansari and Schwer 1995; Jones et al. 1995]. In contrast to the progress in understanding the second
step of splicing in yeast, little is known about the second-step proteins in human splicing. Two proteins, PSF and the U5–200-kD protein, appear to be involved in the second step of splicing (Gozani et al. 1994; Lauber et al. 1996), but their precise functions are unknown. Fractions containing other activities needed for the second step have been described, but none has been purified sufficiently to allow identification of individual proteins (Krainer and Maniatis 1985; Perkins et al. 1986; Lindsey et al. 1995). The paucity of second-step factors known in humans led us to search for the homolog of Prp18.

Of the five splicing snRNPs, only three, the U2, U5, and U6 snRNPs, appear to be required for the second step (for review, see Ares and Weiser 1995; Umen and Guthrie 1995c). The U2 and U6 snRNAs base-pair to each other and to the branch site and 5’ splice site, forming structures necessary for both steps of splicing. A number of mutations in U2 or U6 specifically block the second step (Fabrizio and Abelson 1990; Madhani and Guthrie 1992; McPheeters and Abelson 1992; Wolff et al. 1994). The U5 snRNA base-pairs to exonic sequences at both splice sites (Newman and Norman 1992), possibly aligning the exons for splicing.

Here we report the discovery of a new human protein required for the second step of splicing. The new protein is the homolog of the yeast splicing factor Prp18. The yeast protein can substitute for the human one in the splicing reaction, showing that the mechanism of the pre-mRNA splicing reaction has been highly conserved in evolution. The sequence homology between the yeast and human proteins may define a new protein motif.

Results

Cloning of hPrp18 by degenerate PCR

The similarity of the yeast Prp18 protein sequence to the translations of two short expressed sequence tag (EST) sequences from rice (133 amino acids) and nematode (83 amino acids) suggested that they represent true homologs of Prp18. An alignment of the three sequences was used to design degenerate primers for PCR of human cDNA (Fig. 1). One of the resulting PCR fragments appeared from its sequence to be the desired one and was used to retrieve a full-length cDNA clone from a human cDNA library. The cDNA encodes a new protein, named hPrp18, which is 31% identical and 57% similar to yeast Prp18 (Fig. 1A). hPrp18 is 342 amino acids in length, 91 amino acids longer than yeast Prp18. Homology between the two proteins is strong in the carboxy-terminal third of the proteins [shown boxed in Fig. 1A] but weak elsewhere, where several gaps were introduced to give the displayed alignment. hPrp18 is more similar to the rice and nematode EST sequence fragments than it is to yeast Prp18, and a clear alignment of the four sequences can be made in the carboxy-terminal portion of hPrp18 (Fig. 1B). hPrp18 is not significantly homologous to any protein sequences in the data bases other than the three described here, and it has no known motifs.

The role of hPrp18 in pre-mRNA splicing

To study the function of hPrp18, the protein (with an amino-terminal histidine tag) was produced in Esche-
Richia coli and purified to near homogeneity. Polyclonal antibodies were raised against hPrp18 and were used to deplete HeLa cell nuclear extracts of hPrp18. A Western blot of control and immunodepleted extracts, probed with anti-hPrp18, is shown in Figure 2A. Removal of hPrp18 appears to be complete, because no residual hPrp18 could be detected on long exposure of this blot. A cross-reacting protein with an apparent molecular mass of 55 kD was detected readily by anti-hPrp18; however, it was not significantly depleted by the antibody.

Splicing of β-globin pre-mRNA was assayed in normal and anti-hPrp18 depleted extracts (Fig. 2B). In hPrp18-depleted extract, the second step of splicing was blocked almost completely (Fig. 2B, lanes 9–12). In untreated or pre-immune-depleted extracts (Fig. 2B, lanes 1–4, 5–8), splicing intermediates [exon1 and lariat intron–exon2] were present at low levels during the reaction while the product mRNA accumulated. In anti-hPrp18 depleted extract, the splicing intermediates accumulated during the reaction, and only a trace of mRNA was produced. Quantitation of the gel shown in Figure 2 with a PhosphorImager showed that only the second step was affected by the depletion of hPrp18. The amounts of pre-mRNA remaining at each time point in the pre-immune-depleted and anti-hPrp18-depleted extracts are the same (to within 20%), as are the amounts of RNA processed through the first step (the sum of the molar amounts of intermediates and products).

Purified recombinant hPrp18 could restore full splicing activity to an anti-hPrp18-depleted extract (Fig. 2B, lanes 13–16). hPrp18 was added to anti-hPrp18-depleted extract before the start of the splicing reaction; in this reconstituted extract (Fig. 2, lanes 13–16), the second step of splicing proceeded normally, producing mRNA at levels very similar to those in pre-immune-depleted extract (<20% different from lanes 5–8 in Fig. 2). The first step of splicing was unaffected by the addition of hPrp18. This result shows that hPrp18 was the only essential splicing factor depleted by anti-hPrp18 and establishes that hPrp18 is required for the second step of pre-mRNA splicing.

The splicing intermediates formed in the absence of hPrp18 could be converted to products by the addition of hPrp18. Splicing reactions were carried out for 90 min in the absence of hPrp18 to form spliceosomes containing the lariat intron–exon2 and exon1 intermediates (Fig. 3, lane 1). hPrp18 was added to the reactions, and the amounts of intermediates and products were monitored (Fig. 3, lanes 5–8). Spliced product was formed rapidly on addition of hPrp18 (Fig. 3, lane 5) and accumulated during the 30-min incubation (Fig. 3, lanes 6–8). Quantitation of this gel showed that the intermediates present after 90 min had been converted to products (Fig. 3B). The decrease in the amounts of intermediates was paralleled by the increase in the amount of product mRNA. Because pre-mRNA levels were essentially constant for the first four time points (up to 16 min), the mRNA formed must have come from chasing of the existing intermediates, not from de novo splicing of pre-mRNA. By 30 min, there is a decrease in the amount of pre-mRNA, perhaps because of the recycling of limiting spliceosomal components.

To determine whether hPrp18 is stably associated with spliceosomes during the splicing reaction, we tried to precipitate pre-mRNA, intermediates, or products from splicing reactions with antibodies against hPrp18. We found that very little RNA was immunoprecipitated by anti-hPrp18 from standard splicing reactions (data not

![Figure 2](genesdev.cshlp.org)
pre-mRNA was spliced in a HeLa cell nuclear extract immunodepleted of hPrp18. Splicing was carried out for 90 min in parallel samples (lanes 1,2,5–8). hPrp18 protein was added to these reactions and incubation was continued for 4 min (lane 5), 8 min (lane 6), 16 min (lane 7), or 30 min (lane 8). Lane 2 shows a 30-min incubation without added hPrp18, and lanes 3 and 4 show splicing by extract reconstituted with hPrp18 before the addition of substrate. The positions of the RNAs are indicated as in Fig. 2B. The times shown at the top of each lane are the total reaction times for each sample. (B) Quantitation of the chasing reaction. The amounts of three RNAs, the pre-mRNA (shaded), the lariat intron–exon2 intermediate (hatched), and the mRNA (black), from lanes 1,4–8, and 2 in A were measured. The molar amount of RNA was normalized to the amount of pre-mRNA present at the beginning of the chase. Times indicated in min after the addition of hPrp18.

To increase the fraction of spliceosomes available for hPrp18 binding, splicing reactions were carried out in hPrp18-depleted extracts. Spliceosomes capable of binding hPrp18 were then captured by hPrp18 immobilized on anti-hPrp18–protein A–Sepharose. With this procedure, substantial fractions (20%–30%) of both the lariat intron–exon2 and exon1 intermediates were bound to the hPrp18-resin (Fig. 4, lanes 3,5), implying that hPrp18 is a stable component of the spliceosome before the second transesterification reaction. The precipitation of the RNAs by hPrp18 did not depend on ATP. Only ~3% of the pre-mRNA was precipitated (Fig. 4, lanes 3,5), and similar amounts of pre-mRNA were precipitated in control samples (Fig. 4, lanes 7,9).

Significant amounts of the two products, mRNA and intron, were also precipitated (Fig. 4, lanes 3,5). Under the precipitation conditions, the splicing reaction proceeded, and spliced products were formed from the splicing intermediates when hPrp18 was present (Fig. 4, lanes 3,5,10). This chasing apparently occurred in spliceosomes bound to the resin, as much of the product remained bound, although the possibility that released hPrp18 effected the chase in solution and then rebound to the column cannot be excluded. In the absence of ATP (Fig. 4, lanes 5,6,10), small amounts of spliced products (both mRNA and intron) were formed, and ~30% of these were bound to the column. In the presence of ATP (Fig. 4, lanes 3,4), more products were formed and ~15% of these were bound; the amounts of both splicing intermediates declined (to levels similar to those in lane 2 of Fig. 4), but commensurate amounts of products were not seen. Instability of products under the dilute precipitation conditions is the most likely explanation of this observation, because the intermediates were stable in other samples (Fig. 4, lanes 8,10). The control samples showed that precipitation of splicing intermediates or products required both added hPrp18 protein (Fig. 4, lanes 7,8) and anti-hPrp18 (Fig. 4, lanes 9,10).

Splicing of several pre-mRNAs was assayed in hPrp18-depleted extracts to determine whether hPrp18 is a general splicing factor. In all of the RNAs studied, including the β-thalassemia IVS1-G1 → A (Fig. 5A) (Krainer et al. 1984), ftz (Fig. 5B) (Rio 1988), adenovirus E1A (Fig. 5C) (Schmitt et al. 1987), two β-tropomyosin RNAs, p7(8/9) (Fig. 5D) and p2p6(8/9)pU (data not shown) (Tsukahara et al. 1994), and adenovirus major late (data not shown) (Michaud and Reed 1993), the second step of splicing was substantially inhibited by depletion of hPrp18 and was restored by addition of hPrp18, showing the involvement of hPrp18 in the splicing of all of these substrates. Some residual second-step activity was seen in hPrp18-depleted extracts (Figs. 2B [lane 12] and 5); the amount of activity varied somewhat with different substrates.

The effect of hPrp18 on alternative splicing was tested on pre-mRNAs with duplicated 5’ or 3’ splice sites (Reed and Maniatis 1986, Krainer et al. 1990), as well as the β-thalassemia, adenovirus, and β-tropomyosin RNAs mentioned above. Varying the concentration of hPrp18 did not affect splice site selection in any of these substrates. The results on splicing of various transcripts suggest that by itself hPrp18 does not affect alternative splicing.

**Functional interchangeability of human and yeast Prp18 proteins**

To assess the functional relationship of hPrp18 and yeast Prp18, we carried out both in vitro and in vivo comple-
on Western blots and because the levels of hPrp18 and anti-hPrp18 in the depleted extract are extremely low [neither protein could be detected; Fig. 2A].

We tried to replace yeast Prp18 with hPrp18 in two ways. hPrp18 was tested for complementation of a yeast extract depleted of Prp18 [Fig. 6B]. Depletion of Prp18 blocked the second step of splicing almost completely [Fig. 6B, lanes 1–3], as reported in Horowitz and Abelson (1993a), and full activity was restored on addition of yeast Prp18 [Fig. 6B, lanes 4–6]. Addition of hPrp18, in contrast, did not restore the second step of splicing [Fig. 6B, lanes 7–9], indicating that hPrp18 is inactive in yeast splicing in vitro. hPrp18 was also tested for complementing activity in vivo. The hPrp18 protein was expressed from single- or multicopy plasmids in a yeast strain temperature-sensitive for growth because of the disruption of its PRP18 gene [Horowitz and Abelson 1993b]. hPrp18 did not rescue the yeast cells at nonpermissive temperatures, whereas yeast Prp18 did [data not shown]. Expression of hPrp18 had no evident effect on yeast growth at permissive temperatures. Both the in vitro and in vivo results show that hPrp18 cannot substitute for yeast Prp18.

Association of hPrp18 and the 55-kD protein with the snRNPs

Several methods were used to determine whether hPrp18 is associated with any of the snRNPs. First, snRNPs were fractionated by glycerol gradient sedimentation to resolve the U1, U2, U4/U6, U5, and U4/U6 · U5 snRNPs from one another, as determined by Northern blotting of the snRNAs [Fig. 7A] [Black and Pinto 1989; Behrens and Lührmann 1991]. The position of hPrp18 was determined by Western blotting of gradient fractions [Fig. 7B]. hPrp18 was found only at the top of the gradient, indicating that the vast majority of hPrp18 was not stably bound to any of the snRNPs. Under all of the tested conditions, we found that hPrp18 remained principally at the top of the gradient and did not comigrate with any of the snRNPs. Second, snRNAs were immunoprecipitated with antitrimethylguanosine under conditions where the snRNPs remain intact [Krainer 1988]. No significant amount of hPrp18 was precipitated with the snRNPs [assayed by Western blot; data not shown], consistent with the glycerol gradient results. Finally, no hPrp18 was found in a preparation of purified U4/U6 · U5 snRNPs [data not shown; Behrens and Lührmann 1991]. All of the results are consistent with the conclusion that hPrp18 is not stably associated with any of the snRNPs.

The experiments on snRNPs showed unexpectedly that the 55-kD protein that cross-reacts with anti-hPrp18 is part of the U4/U6 snRNP. In glycerol gradient fractionation, the 55-kD protein cosedimented with U4/U6 and U4/U6 · U5. The 55-kD protein peaked in fractions 17 and 18 at the same place as the U4/U6 · U5 snRNP [Fig. 7]. A smaller peak of 55-kD protein was seen in fractions 10–12, comigrating with the similarly small peak of U4/U6 snRNP. Unbound 55-kD protein re-
Figure 5. Splicing of different pre-mRNAs in hPrp18-depleted extract. Splicing was assayed on four substrates: (A) β-thalassemia (β-globin IVS1-G1 → A); (B) ftz exons 1 and 2; (C) adenovirus E1A; and (D) β-tropomyosin exons 7 and 8/9. Each panel shows the products of three splicing reactions using untreated extract (lane 1); hPrp18-immunodepleted extract (lane 2); and hPrp18-depleted extract plus hPrp18 protein (lane 3). The positions of the various RNAs are shown. The mRNAs resulting from use of cryptic sites 1, 2, and 3 (cr1, cr2, and cr3) in the β-thalassemia pre-mRNA are indicated [A]. The cr2 site is dominant and only its intermediates can be identified readily; the band corresponding to the cr1 lariat intermediate is also indicated. The intermediates and products in splicing of E1A [C] were assigned by comparison with Schmitt et al. (1987). The 13S lariat intermediate and product were reported previously to be multiple bands. Part of the gel has been omitted; the bottom panel in C, showing the 13S lariat, is from a slightly darker exposure than the top one. The bands marked with an asterisk were noted but not assigned in Schmitt et al. [1987]. More activity is seen with untreated extract [lane 1] than with restored extract [lane 3] because of nonspecific reduction in activity caused by the depletion procedure [also seen for β-globin in Fig. 2].

Figure 6. (A) Reconstitution of human splicing activity with yeast Prp18. Splicing of β-globin pre-mRNA in HeLa cell nuclear extract depleted of hPrp18 [lanes 1,2], with hPrp18 [lanes 3,4], or with yeast Prp18 [lanes 5,6], carried out for the indicated times. The positions of the RNAs are indicated as in Fig. 2B. In this assay, splicing with yeast Prp18 produced ~40% as much mRNA (with a concomitant reduction in lariat intron-exon2 and exon1 intermediates) as did splicing with hPrp18. Yeast Prp18 did not affect the first step of the reaction. (B) Attempt to reconstitute yeast splicing activity with hPrp18. Splicing of actin pre-mRNA in a yeast extract immunodepleted of Prp18 [lanes 1–3], with yeast Prp18 [lanes 4–6], or with hPrp18 [lanes 7–9], carried out for the indicated times. Splicing in pre-immune-depleted extract is also shown [lanes 10–12]. The positions of the RNAs are indicated. Lanes 1–3 are virtually indistinguishable from lanes 7–9, suggesting that hPrp18 is inactive in yeast splicing. hPrp18 did not affect either step of splicing of actin pre-mRNA in a normal yeast extract (data not shown).

These results show that the 55-kD protein is associated with the U4/U6 snRNP. Antibodies raised against hPrp18 were used to immunoprecipitate snRNAs from nuclear extract [Fig. 8]. Pri-
U5 in the U4/U6 snRNP particle. Free U5 snRNP sedi-
precipitation of U4 and U6 was specific but inefficient:

blotting. The U1 snRNP (fractions 6-8) and the U2 snRNP (frac-
tions just behind the U4/U6 peak) precipitated together as a single particle, giving the small peak in frac-
tions 12-13) sediment as individual particles. U4 and U6 sedi-
ment as individuals. U4 and U6 sediment together as a single particle, giving the small peak in frac-
tions 10-12 and a larger peak in fractions 17-18, together with U5 in the U4/U6 U5 snRNP. Fraction numbers are shown along the bottom. The U1, U2, U4, U5, and U6 snRNAs from each fraction were separated on a denaturing polyacrylamide gel and detected by Northern blotting. The U1 snRNP (fractions 6-8) and the U2 snRNP (fractions 12-13) sediment as individual particles. U4 and U6 sedi-
ment together as a single particle, giving the small peak in frac-
tions 10-12 and a larger peak in fractions 17-18, together with U5 in the U4/U6 U5 snRNP. Free U5 snRNP sedi-
ments just behind the U4/U6 U5 snRNP, peaking in fraction 15. The relative sedimentation of the snRNPs is consistent with other reports (Black and Pinto 1989; Behrens and Lührmann 1991). (B) Western blot of glycerol gradient fractions. Glycerol

Figure 7. (A) Northern blot of glycerol gradient fractions. HeLa cell nuclear extract was pre-incubated under splicing conditions and then fractionated in a glycerol gradient (Black and Pinto 1989). Fraction numbers are shown along the bottom. The U1, U2, U4, U5, and U6 snRNAs from each fraction were separated on a denaturing polyacrylamide gel and detected by Northern blotting. The U1 snRNP (fractions 6-8) and the U2 snRNP (fractions 12-13) sediment as individual particles. U4 and U6 sedi-
ment together as a single particle, giving the small peak in frac-
tions 10-12 and a larger peak in fractions 17-18, together with U5 in the U4/U6 U5 snRNP. Free U5 snRNP sedi-
ments just behind the U4/U6 U5 snRNP, peaking in fraction 15. The relative sedimentation of the snRNPs is consistent with other reports (Black and Pinto 1989; Behrens and Lührmann 1991). (B) Western blot of glycerol gradient fractions. Glycerol gradient fractions were probed with antibody against hPrp18. Cross-reactivity with the 55-kD protein is discussed in the text. Fraction numbers are shown along the bottom.

Figure 8. Immunoprecipitation of snRNAs by anti-Prpl8. snRNAs were immunoprecipitated from HeLa cell nuclear extract using pre-immune antibodies or antibodies raised against hPrp18. Salt concentrations varying from 50 to 600 mM were used, as indicated at the top of each lane. A Northern blot of the precipitated snRNAs is shown. The positions of the five snRNAs probed are indicated. In the lane showing total RNA, only one-fifth of the amount of sample used for each of the immunoprecipitations was loaded.

A human second-step splicing factor

primarily the U4 and U6 snRNAs were precipitated at moderate salt concentrations (100-400 mM). The immuno-
precipitation of U4 and U6 was specific but inefficient: Less than 1% of the U4 or U6 snRNA present in the extract was precipitated. Precipitation of U4 and U6 was not affected by preincubation of extracts under splicing conditions. The U1 and U2 snRNAs were precipitated only at low salt (50 mM), probably through weak interactions with the U4 and U6 snRNPs. Precipitation of small amounts of U5 snRNA at 100-150 mM salt is probably attributable to the association of the U5 snRNP with the U4/U6 snRNP (Will and Lührmann 1996). At 600 mM salt, more U5 was precipitated than at lower salt concentrations. This precipitation was seen at salt concent-
trations up to 1200 mM (data not shown) and was abolished by preincubation of extracts under splicing conditions. We believe that the U4 and U6 snRNPs are coimmunoprecipitating with the 55-kD protein, consistent with our other results. The low efficiency of the immunoprecipitation could result from the failure of anti-hPrp18 to recognize the native 55-kD protein effi-
ciently [as in the immunodepletions; see Fig. 2A]. However, we cannot exclude the possibility that hPrp18 binds to the U4 or U6 snRNP in amounts too small to be detected in the glycerol gradients and that it mediates the coimmunoprecipitation.

We do not know whether the 55-kD protein is related to hPrp18. All of the polyclonal antibodies raised against hPrp18 (two in rabbits, one in mice) cross-reacted with the 55-kD protein. However, we did not find any direct evidence to suggest that it is related to hPrp18. Only one mRNA was detected in northern blots using hPrp18 cDNA as the probe, suggesting that there are no alter-
atively spliced forms of hPrp18. Two results suggest that the 55-kD protein is not a posttranslationally modified form of hPrp18: first, His-tagged hPrp18, added to HeLa cell extracts under conditions where it is active in splicing, was not modified to any forms with different electrophoretic mobilities; and, second, in vitro translation in rabbit reticulocyte or wheat germ extract gave only the 40-kD product expected for hPrp18. Curiously, anti-
body against yeast Prp18 reacts with a 54-kD human protein, called p54

Discussion

We have identified and characterized a new human pre-
mRNA splicing factor required for the second catalytic step of splicing. The new protein, hPrp18, was found using degenerate PCR based on the sequences of yeast Prp18, a rice EST, and a nematode EST. Homology between hPrp18 and yeast Prp18 is strong only in part of the protein, yet the yeast protein can substitute for the human one in human splicing. In HeLa cell nuclear ex-
tracts immunodepleted of hPrp18, the first step of splicing proceeds normally, but the second step is blocked.
Addition of purified hPrp18 protein to depleted extracts restores full splicing activity, proving that hPrp18 is a second-step splicing factor. The splicing intermediates formed in the absence of hPrp18 can be chased to products by hPrp18, showing that the spliceosomes containing these intermediates are functional and suggesting that they are normal intermediates in the splicing pathway.

hPrp18 is required for the second step of splicing of all of the pre-mRNAs we tested, strongly suggesting that hPrp18 is a general splicing factor. A small amount of product mRNA was observed in the splicing of each of the pre-mRNAs in hPrp18-depleted extracts, different pre-mRNAs gave slightly different amounts of residual second-step activity, but we did not find any pre-mRNA that spliced efficiently in depleted extracts. The residual activity may result from traces of hPrp18 remaining in the extract, although none was detected by Western blot. Alternatively, the residual activity may be from hPrp18-independent splicing, as was seen in yeast, in which Prp18 is not absolutely required and splicing occurs slowly without it (Horowitz and Abelson 1993a,b).

The first evidence that there are factors specific to the second step of splicing was obtained by biochemical methods (Krainer and Maniatis 1985; Perkins et al. 1986). However, the complete purification of these activities has not been reported. Recently, an activity required for the second step of splicing has been partly characterized (Lindsey et al. 1995). This activity was able to chase spliceosome-bound intermediates to products in the absence of ATP, also a property of hPrp18 and yeast Prp18 as well as yeast S7 [Horowitz and Abelson 1993a; Ansari and Schwer 1995; Jones et al. 1995]. Two observations suggest that hPrp18 is distinct from, or is only a part of, this activity. First, yeast Prp18 could not substitute for the activity [Lindsey et al. 1995] in contrast to our results for hPrp18, and second, the activity is found in a large particle [Lindsey et al. 1995], whereas hPrp18, which is found at the top of glycerol gradients, does not appear to be part of a complex.

Recent work has suggested that two proteins are involved in the second step of splicing. A 200-kD, U5 snRNP-associated protein has been implicated in the second step of splicing by antibody-inhibition experiments [Lauber et al. 1996]. However, the yeast homolog of the U5-200-kD protein is required for the first step of splicing in vivo [Lauber et al. 1996; Noble and Guthrie 1996] and in vitro [Xu et al. 1996]. The results for the yeast protein support the idea (Lauber et al. 1996) that the antibody inhibition experiments may have uncovered only part of the function of the human U5-200-kD protein or that the second step may have been inhibited indirectly by steric hindrance of splicing by antibodies within the spliceosome.

The PSF protein has also been implicated in the second step of splicing [Gozani et al. 1996], although high levels of anti-PSF also block the first step [Patton et al. 1993]. To date, PSF has only been shown to be required for the splicing of a pre-mRNA derived from the α-tropomyosin pre-mRNA, the substrate has an unusual branch point, located far from the 3’ splice site, just upstream of a second pyrimidine tract [Smith and Nadal-Ginard 1989]. Because PSF binds preferentially to RNAs with pyrimidine tracts [Patton et al. 1993], it may only be required for splicing of specific RNAs with such tracts. Therefore, hPrp18 may be the first general second-step factor found in humans.

Isolation of spliceosomes containing splicing intermediates has allowed the identification of several proteins that join the spliceosome after the initial steps of spliceosome assembly [Gozani et al. 1994]. Based on their molecular weights, two of these proteins, a 40-kD U5 snRNP protein [Bach et al. 1989] and SAP45, could be hPrp18. However, the 40-kD protein is not hPrp18, as the 40-kD protein is present in the purified U4/U6·U5 snRNPs that we tested [Behrens and Lührmann 1991] but is not detected by anti-hPrp18; in addition, the electrophoretic mobilities of the 40-kD protein and hPrp18 are slightly different. We do not know whether hPrp18 is the same as SAP45.

hPrp18 binds transiently to the spliceosome during the second step of splicing. From splicing reactions done with hPrp18-depleted extract, splicing intermediates could be efficiently precipitated on immobilized hPrp18. Some of the spliceosomes bound to the immobilized hPrp18 carried out the second step of splicing, forming products that remained bound to the column. In contrast, from normal splicing reactions, only a very small fraction of any splicing RNA could be precipitated with anti-hPrp18. hPrp18 apparently binds the spliceosome transiently only at the point in the splicing reaction when it is needed. The low yield of immunoprecipitations from standard splicing reactions implies that the association of hPrp18 with the spliceosome is normally short-lived, even among spliceosomes containing intermediates or products, only a small fraction appear to contain hPrp18. The results support a model in which hPrp18 binds to the spliceosome just before the second transesterification reaction, after other stages within the second step. Following the reaction, hPrp18 remains bound to the spliceosome bearing the products, but it is eventually released, perhaps when the spliceosome disassembles.

Two second-step factors in yeast associate transiently with the spliceosome. The Prp16 protein binds to spliceosomes containing intermediates, catalyzes a conformational change in the spliceosome fueled by ATP hydrolysis, and then leaves the spliceosome [Schwer and Guthrie 1991, 1992; Brys and Schwer 1996]. Prp16 acts before Prp18 [Horowitz and Abelson 1993a] and does not appear [by immunoprecipitation] to be part of the spliceosome at the time of the second transesterification reaction. The Slu7 protein acts after Prp16, at the same stage of the second step as Prp18 [Ansari and Schwer 1995; Jones et al. 1995]. Strong binding of Slu7 to the spliceosome depends on Prp16, and Slu7 remains bound to the spliceosome during the second reaction [Brys and Schwer 1996]. Release of Slu7 from the spliceosome occurs only on disassembly of the spliceosome. Our results on spliceosome binding by hPrp18 closely parallel those for Slu7. The behavior of the Prp8 protein is different; it
appears to be associated stably with the spliceosome throughout the splicing reaction (Whittaker et al. 1990).

One possible site of binding of hPrp18 in the spliceosome is the U5 snRNP. Yeast Prp18 is associated with the U4/U6·U5 snRNP, primarily through interaction with the U5 snRNP (Horowitz and Abelson 1993b). However, the results for hPrp18 are different, and we found no evidence of a stable association between hPrp18 and any of the snRNPs. Although the difference in snRNP-binding properties of hPrp18 and Prp18 may reflect a fundamental difference in the mechanisms of action of the two proteins, the functional interchangeability of the proteins in human splicing argues that they are mechanistically similar. Prp18 is not bound tightly to U4/U6·U5, compared with other yeast proteins such as Prp4 and Prp24 (Banroques and Abelson 1989; Petersen-Bjørn et al. 1989; Shannon and Guthrie 1991), and we suspect that in hPrp18 these interactions have been weakened further.

Antibodies raised against hPrp18, a 40-kD protein, cross-react with a 55-kD protein on Western blots. Although we do not know what the relationship of the 55-kD protein is to hPrp18, the 55-kD protein does not appear to be either a modified form or an alternatively spliced form of hPrp18. The 55-kD protein is associated with the U4/U6 snRNP. Two other U4/U6-specific proteins are known, one of 60-kD and one of 90-kD, but neither has been characterized (Gozani et al. 1994). From their electrophoretic mobilities, it is possible that the 55-kD and 60-kD protein are the same. Three other snRNP proteins of 60 kD have also been reported; they appear to be part of the U4/U6·U5 snRNP (Behrens and Lührmann 1991; Will and Lührmann 1997). Five proteins associated specifically with U4/U6 are known in yeast (Banroques and Abelson 1989; Petersen-Bjørn et al. 1989; Abovich et al. 1990; Shannon and Guthrie 1991; Cooper et al. 1995).

The interchangeability of hPrp18 and yeast Prp18 in human splicing was surprising given the relatively weak overall similarity of their sequences (Fig. 1A). During the second step of splicing, hPrp18 is likely to interact with several components of the spliceosome. Yeast Prp18 binds to the U4/U6·U5 snRNP (Horowitz and Abelson 1993b), and genetic experiments suggest that it interacts with the Prp17 and Slu7 proteins, as well as the U5 snRNA (Frank et al. 1992; Jones et al. 1995), and we expect that hPrp18 would require similar interactions.

We do not know why the complementation results in human and yeast splicing are asymmetric. The replacement of hPrp18 with yeast Prp18 in human splicing implies that they function very similarly and that they share many structural features. The failure of hPrp18 to function in yeast splicing may be attributable to minor functional differences in the proteins or to technical difficulties in the experiments [for example, instability of the protein or improper protein localization]. A possible explanation for the failure of hPrp18 to function in yeast is that yeast splicing may require a stronger interaction between Prp18 and the U4/U6·U5 snRNP. Despite the conservation of at least one portion of hPrp18 in yeast Prp18, hPrp18 did not function as a dominant negative allele of PRP18 in yeast; such a result might be expected if a conserved part of hPrp18 interacted with, and sequestered, another essential splicing factor.

The complementation results imply that important functional domains of hPrp18 are conserved in Prp18. Figure 1A shows that strong homology between the two proteins is restricted to the carboxy-terminal part of the proteins. Within the boxed portion of the sequences, 40% of the amino acids are identical; however, outside this region the alignment is weak, implying that the carboxy-terminal domain is critical for the functioning of hPrp18. The alignment of the carboxyl termini of hPrp18 and yeast Prp18 with the rice and nematode EST sequences [Fig. 1B] shows that this region is highly conserved among all the proteins. Homology is focused in two areas, from amino acids 273–291 and from 303–324, where a consensus sequence can be readily derived. Although a variety of search programs failed to find other proteins related to these in the current data bases, we suggest that this alignment defines a new protein motif. Neither our data nor the data base searches suggest what the function of this evolutionarily conserved region is. It may be involved in interaction with proteins or RNAs, or it may carry out a specific task in the splicing reaction.

Several other homologous splicing proteins in humans and yeast have been identified. These include components of the SF3a and SF3b complexes, which act early in the spliceosome assembly pathway (Behrens et al. 1993; Bennett and Reed 1993; Brosi et al. 1993; Krämer et al. 1995; Gozani et al. 1996; Wells et al. 1996); four snRNP proteins (Smith and Barrell 1991; Liao et al. 1993; Rymond et al. 1993; Polycarpou-Schwarz et al. 1996); and a member of the DEAH protein family (called HRH1) that functions in spliceosome disassembly (Ono et al. 1994). The recently identified human U5–200-kD protein, whose yeast homolog is known as Brtr2, Slt22, or Snu246 [Noble and Guthrie 1996; Xu et al. 1996], is both a DEXH protein and a snRNP-associated protein [Lauber et al. 1996]. A homolog of Prp8, which is involved in both steps of splicing, has been identified using antibodies [Pinto and Steitz 1989; Garcia-Blanco et al. 1990; Hodges et al. 1995]. In these homologs, overall sequence identity [when known] ranges from 25% to 45%. The human snRNP D1 protein [Rymond et al. 1993], and the HRH1 protein [Ono et al. 1994], two of the most conserved homologs, are functional in vivo in yeast. However, Prp18 is the only yeast splicing factor demonstrated to function in human splicing.

Although pre-mRNA splicing in yeast and mammals follows similar overall pathways, there are some notable differences. The mechanism for recognizing splice sites in mammals, which allows for wide variation in splice-site sequences and for regulated alternative splicing, is more complex than that of yeast, where splice-site sequences are nearly invariant and alternative splice-site selection is absent (Horowitz and Krainer 1994; Black 1995). Identification of 3′ splice sites, which occurs during the second step, is likely, therefore, to occur by

---

A human second-step splicing factor

GENES & DEVELOPMENT 147

---
Horowitz and Krainer

somewhat different mechanisms in mammals and yeast. Previous work on the second step of splicing in mammals has focused on the snRNAs and the pre-mRNA. Experiments on the U2 and U6 snRNAs, which are both required for the second step of splicing, have generally supported the conservation of splicing mechanism between yeast and humans (Fabrizio and Abelson 1990; Shuster and Guthrie 1990; Datta and Weiner 1993; Wolff et al. 1994; Ares and Weiser 1995). In the work reported here, we have characterized a protein required for the second step. The conservation of its function between yeast and humans shows the close phylogenetic conservation of the mechanism of the splicing reaction.

Materials and methods

Identification and cloning of the hPrp18 cDNA

Alignment of the yeast (L03536), nematode [T01256], and rice (D15798) sequences was the basis for designing two oligonucleotides, 5'-CGGAATTCGC(I/C)AT(I/C)GG(I/C)AATGC(T/C)GC-3' and 5'-CGGGATCCGATGTATTT(G/T)CIG(T/C)TCGTC-3' [corresponding to amino acids 187–194 and 230–232 of the yeast sequence], that were used for PCR of human cDNA. A fragment of the expected size was generated, its sequence could be aligned with the yeast, rice, and nematode peptide sequences. Two oligonucleotides corresponding to portions of this fragment were used to screen a λ HeLa cDNA library. The resulting clone, containing a 1450-bp insert, was sequenced (accession no. U51990). A Northern blot of poly(A)+ RNA from HeLa cells gave a single, diffuse band of ~-1600 bases, suggesting that the DNA clone was full-length. The first ATG codon in the hPrp18 sequence was presumed to be the correct one based on its frame and context (Grünert and Jackson 1994); protein produced in E. coli comigrated exactly with HeLa cell protein detected by Western blots. Several human ESTs that overlap the sequence of hPrp18 have been reported since the completion of this work. The EST sequences are 96%-99% identical to our hPrp18 sequence. Analysis of the DNA and protein sequences was done using the GCG package (Genetics Computer Group 1994).

Production of recombinant hPrp18 and antibodies

The hPrp18 protein with or without an amino-terminal oligohistidine tag was made in E. coli using the T7 expression vectors pET9c and pET19b (Novagen). His-tagged hPrp18, which formed inclusion bodies, was purified to near homogeneity by immobilized metal-ion affinity chromatography in 6 M guanidinium HCl (Petty 1993) and then renatured by dialysis against 25 mM Tris at pH 7.5, 250 mM NaCl, 1 mM EDTA, 1 mM DTT, and 10% glycerol. The purified protein was mostly soluble and was stable for >1 year at 4°C. The His-tagged hPrp18 was used for raising antibodies and for functional studies.

Immunodepletion of hPrp18

hPrp18 was immunodepleted from HeLa cell nuclear extracts by incubating extracts with one-fifth volume of protein A-Sepharose-bound antibodies in 20 mM HEPES at pH 7.9, 750 mM KCl, 10% glycerol, 1 mM DTT, 0.2 mM EDTA, 0.1 mM PMSF for 1 hr at 4°C twice, followed by incubation with one-tenth volume protein A-Sepharose in the same buffer for 30 min to remove any released antibody. The depleted extract was dialyzed against the same buffer with 100 mM KCl. Immunoprecipitations from 35S-labeled nuclear extract showed that hPrp18 was the predominant precipitated protein. The 55-kD protein could not be detected in Western blots of the proteins immunoprecipitated under hPrp18-depletion conditions.

Splicing assays

Splicing in HeLa-cell nuclear extracts was carried out as described previously (Krainer et al. 1984). For reconstitution of splicing activity, 10-50 ng purified recombinant hPrp18 was added per microliter of nuclear extract (7 µg protein). From Western blots we estimated that the concentration of hPrp18 in our HeLa nuclear extracts was 5 ng/µl; we obtained essentially full restoration of splicing with 2 ng of recombinant hPrp18 per microliter extract. For reconstitution of activity with yeast Prp18, 100 ng Prp18 was added per microliter HeLa nuclear extract. Splicing substrates were transcribed from pSP64-HBJ6 [Krainer et al. 1984], pSP64-HβΔfVS1-IA [Krainer et al. 1984], pSP64-Hβ5′D16X [Reed and Maniatis 1986; Krainer et al. 1990], pSP64-Hβ3′D115 [Reed and Maniatis 1986; Krainer et al. 1990], p7/8/9 [Tsukahara et al. 1994], p2p6/8/9pU [Tsukahara et al. 1994], pSF6-Sp (Schmitt et al. 1987), Sp6–fiz [Rio 1988], and pAdML (Michaud and Reed 1993).

Yeast splicing, immunodepletion of Prp18 from yeast extracts, and purification of Prp18 protein were carried out as described previously (Lin et al. 1985; Horowitz and Abelson 1993a). Forty nanograms hPrp18 [40 ng] was added per microliter of yeast extract in our attempt to restore activity to the Prp18-depleted extract.

Immunoprecipitation of spliceosomes

Antiserum against hPrp18 (or pre-immune serum) was incubated with protein A-Sepharose [3 µl serum per microliter resin]. After extensive washing, the resin was incubated with hPrp18 [50 ng per microliter resin] and washed again, yielding hPrp18–anti-hPrp18–protein A-Sepharose. Splicing reactions were carried out in hPrp18-depleted extracts for 90 min under normal splicing conditions except that polyvinylalcohol was omitted, diluted 10-fold either in splicing buffer or in ATP-depleting splicing buffer (including glucose and hexokinase, but lacking creatine phosphate and ATP); brief incubation in this buffer reduced the concentration of ATP to ~0.3 µM), and mixed with the hPrp18–anti-hPrp18–protein A-Sepharose. The mixture was spun in a microcentrifuge filter, separating the resin from the unbound material; the resin was washed once briefly, and the wash was removed by filtration and combined with the unbound fraction. Bound RNA was eluted from the resin with proteinase K and SDS.

Expression of hPrp18 in yeast

The hPrp18 gene was placed under control of the GAL1 promoter using the plasmids pSERC65GAL [single copy] and pSSEY18GAL [multicopy] (Herman and Emr 1990). hPrp18 did not rescue the temperature-sensitive defect of the yeast PRP18 knockout strain DH120R (Horowitz and Abelson 1993b) at 33°C or 37°C under a variety of induction conditions. At 23°C (a permissive temperature) expression of hPrp18 had no apparent effect on yeast growth. Expression of hPrp18 in yeast was verified by Western blot. Yeast Prp18 expressed from analogous plasmids always rescued the yeast.
**Glycerol gradients**

Glycerol gradients were run according to described procedures [Black and Pinto 1989; Behrens and Lührmann 1991], both with and without preincubation under splicing conditions. RNAs were detected on Northern blots with RNA probes (Konarska and Sharp 1987). hPrp18 and the 55-kD protein were detected by Western blotting using enhanced chemiluminescence.

**Immunoprecipitations of snRNPs**

Immunoprecipitations using antibodies against trimethylguanosine or hPrp18 were carried out according to procedures described previously (Krainer 1988; Banroques and Abelson 1989; Horowitz and Abelson 1993b).

**Acknowledgments**

We thank M. Konarska, A.R. Kerlavage, A. Mayeda, R. Reed, and D. Helfman for plasmid DNAs, C. Will and R. Lührmann for purified snRNPs; M. Meyer for 35S-labeled extract, J. Cáceres, G. Sceaton, M. Stratham, D. DeWald, R. Pruzan, and K. Collins for helpful discussions; and M. Selvakumar, M. Murray, J. Cáceres, and C. Autexier for comments on the manuscript. This work was supported by National Institutes of Health grants GM42699 and by a scholarship from the Pew Charitable Trusts to A.R.K.

The publication costs of this article were defrayed in part by payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 USC section 1734 solely to indicate this fact.

**References**


Horowitz, D.S. and J. Abelson. 1993a. Stages in the second re-
action of pre-mRNA splicing: The final step is ATP independ-
—. 1993b. A US small nuclear ribonucleoprotein particle
protein involved only in the second step of splicing in Sac-
Horowitz, D.S. and A.R. Krainer. 1994. Mechanisms for select-
ing 5′ splice sites in mammalian pre-mRNA splicing. Trends
Genet. 10: 100-106.
Jones, M.H., D.N. Frank, and C. Guthrie. 1995. Characteriza-
tion and functional ordering of Slu7p and Prp 17p during the
Sci. 92: 9687-9691.
small nuclear ribonucleoprotein particles in formation of
Krainer, A.R. 1988. Pre-mRNA splicing by complementation
with purified human U1, U2, U4/U6 and U5 snRNPs. Nucleic
Acids Res. 16: 9415-9429.
the small ribonucleoproteins U1 and U2 are necessary for
Normal and mutant human β-globin pre-mRNAs are faith-
pre-mRNA splicing factor SF2 influences 5′ splice site selec-
Krämer, A. 1996. The structure and function of proteins in-
volved in mammalian pre-mRNA splicing. Annu. Rev. Bio-
chem. 65: 367-409.
1995. Mammalian splicing factor SF3a120 represents a new
member of the SURF family of proteins and is homologous
to the essential splicing factor PRP21 of Saccharomyces cerevisiae.
RNA 1: 250-272.
Lauber, J., P. Fabrizio, S. Teigelkamp, W.S. Lane, E. Hartmann,
and R. Lührmann. 1996. The HeLa 200 kDa U5 snRNP-specific
protein and its homologue in Saccharomyces cerevisiae
are members of the DEXH-box protein family of puta-
tive RNA helicases. EMBO J. 15: 4001-4015.
identifies a gene that encodes the yeast U1 snRNP A protein:
Implications for snRNP protein function in pre-mRNA splic-
ing. Genes & Dev. 7: 419-428.
Yeast mRNA splicing in vitro. J. Biol. Chem. 260: 14780-
14792.
products are essential for mRNA splicing in vitro. Cell
47: 953-963.
Madhani, H. and C. Guthrie. 1992. A novel base-pairing inter-
action between U2 and U6 snRNAs suggests a mechanism for
the catalytic activation of the spliceosome. Cell 71: 803-817.
the yeast U2 snRNA suggests a structural similarity to the
Michaud, S. and R. Reed. 1993. A functional association be-
tween the 5′ and 3′ splice sites is established in the earliest
prespliceosome complex (E) in mammals. Genes & Dev. 7:
1008-1020.
exon sequences at 5′ and 3′ splice sites. Cell 68: 743-754.
required for yeast pre-mRNA splicing by means of cold-
putative RNA helicase [HRH1], a human homolog of yeast
Patton, J.G., E.B. Porro, J. Galceran, F. Tempst, and B. Nadal-
pre-mRNA splicing factor. Genes & Dev. 7: 393-406.
Perkins, K.K., H.M. Fumeaux, and J. Hurwitz. 1986. RNA splic-
ing products formed with isolated fractions from HeLa cells
Acad. Sci. 83: 887-891.
PRP4 [RNA4] from Saccharomyces cerevisiae: Its gene prod-
uct is associated with the U4/U6 small nuclear ribonucleo-
Petty, K.J. 1993. Metal-chelate affinity chromatography. In Cur-
rent protocols in molecular biology. John Wiley & Sons,
New York, NY.
Pinto, A.L. and J.A. Steitz. 1989. The mammalian analogue of
the yeast Prp8 splicing protein is present in the U4/S/6
small ribonucleoprotein particle and the spliceosome. Proc.
Poggeri, P., G. Scherer, M., S.I. Gunderson, S. Kandels-Lewis, B.
Séraphin, and I.W. Mattaj. 1996. Drosophila Snf/DC5 com-
bines the functions of the two snRNP proteins U1A and
U2BP that are encoded separately in human, potato, and
yeast. RNA 2: 11-23.
Reed, R. and T. Maniatis. 1986. A role for exon sequences and
splice-site proximity in splice-site selection. Cell 46: 681-
690.
Rio, D.C. 1988. Accurate and efficient pre-mRNA splicing in
85: 2904-2908.
snRNP polypeptide D1 promotes pre-mRNA splicing in
yeast and defines nonessential yeast Smd1p sequences.
Nucleic Acids Res. 21: 3501-3505.
Alternative splicing of E1A transcripts of adenovirus
requires inappropriate ionic conditions in vitro. Cell 50:
31-39.
Schwer, B. and C. Guthrie. 1991. PRP16 is an RNA-dependent
ATPase that interacts transiently with the spliceosome. Na-
ture 349: 494-499.
—. 1992. A conformational rearrangement in the splice-
osome is dependent on PRP16 and ATP hydrolysis. EMBO J.
11: 5033-5039.
snRNA mutation define a novel U6 snRNP protein with
RNA-binding motifs. Genes & Dev. 5: 773-785.
Shuster, E.O. and C. Guthrie. 1990. Human U2 can function in
splicing of α-tropomyosin exons enforced by an unusual
lariat branch point location: Implications for constitutive
Teigelkamp, S., E. Whitaker, and J.D. Beggs. 1995. Interaction
of the yeast splicing factor PRP8 with substrate RNA during
both steps of splicing. Nucleic Acids Res. 23: 320-326.
Tsukahara, T., C. Casciato, and D.M. Helfman. 1994. Alterna-
}


———. 1995b. Prp16p, Slu7p, and Prp8p interact with the 3' splice site in two distinct stages during the second catalytic step of pre-mRNA splicing. *RNA* 1: 584–597.


